EDA2R/TNFRSF27/XEDAR Antibody - BSA Free

X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappaB and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 1 application: IHC-P.

Showing Publication 1 - 1 of 1.

Publication using NBP1-76710	Applications	Species
Westland R, Verbitsky M, Vukojevic K et al. Copy number variation analysis identifies novel CAKUT candidate genes in children with a solitary functioning kidney. Kidney Int. 2015-09-09 [PMID: 26352300] (IHC-P, Human, Mouse)	IHC-P	Human, Mouse

Array NBP1-76710

• EDA2R/TNFRSF27/XEDAR Antibodies
• EDA2R/TNFRSF27/XEDAR Lysate
• EDA2R/TNFRSF27/XEDAR Protein
• EDA2R/TNFRSF27/XEDAR Proteins and Enzymes
• EDA2R/TNFRSF27/XEDAR ELISA